As we wait for data and information regarding to our path forward, I just wonder what would happen if the FDA told us that we need to run new trials for both Alzheimer’s and Rett . If that is the path that the FDA put us on, I would suspect that we would be in dire need for additional funding. Alzheimer’s itself will take at least 2 to 3 years to get through the process. I would also assume that we would need approximately 750 to 1000 patients This is based on previous phase 2/3 trial for Alzheimer’s and certainly getting 200 patients on board for a new Rett trial will be tough. With that said, I would think we would need at least another hundred million dollars to make all this happen. So my question is do we partner for both indications at that point in time and let the partner do the trials or do we sell the company. What kind of upfront payments would we receive for partnering on Alzheimer’s and let them do the trials? Now they are taking the risk.
Market Data 
Markets 
AI
